## Biopolymeric carriers developed for tissue engineering application and fabricated by Supercritical Emulsion Extraction

Erwin Pavel Lamparelli<sup>1</sup>, Ida Palazzo<sup>2</sup>, Ernesto Reverchon<sup>2</sup>, Nicola Maffulli<sup>1</sup> and Giovanna Della Porta<sup>1,3</sup>

- (1) Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana" University of Salerno, Via S. Allende 1, 84081 Baronissi (SA), IT.
- (2) Department of Industrial Engineering, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano (SA), IT.
- (3) Centro Interdipartimentale BIONAM, Università di Salerno, Via G. Paolo I, Fisciano (SA), Italy.

Controlled delivery of human growth factors is still an open challenge in the tissue engineering field, especially in tridimensional cultures using scaffold as support [1-2]. For this task, poly-lactic acid (PLA) and poly-lactic-co-glycolic acid (PLGA) carriers have been recently proposed [3-4].

Here, the microencapsulation of Growth Differentiation Factor 5 (hGDF-5) and Transforming Growth Factor  $\beta$ 1 (hTGF- $\beta$ 1), used respectively to induce tenogenesis and chondrogenesis, was tested by processing different emulsions with Supercritical Emulsion Extraction (SEE) technology [5-6]. Polymers molecular weight, surfactant amount in aqueous phases of emulsions as well as phases mixing rate were varied to fabricate carriers with suitable size and loadings. Carriers with mean sizes from 0.4 ± 0.09 µm up to 3 ± 0.9 µm were obtained by SEE technology when processing emulsions with different formulations; carriers were loaded with 3 µg/g and 7 µg/g for hGDF-5 and hTGF- $\beta$ 1 and both assured *in vitro* a controlled growth factor release over 25 days. Carriers fabricated by SEE displayed extremely low cytotoxicity with respect to carriers obtained by conventional evaporation techniques as tested by Hamster Ovary cells line as well as lower reactivity on human peripheral blood mononuclear cells (hPBMCs), suggesting their safety and potential use in tissue engineering protocols.

## References

- 1. Lamparelli, E.P., Lovecchio, J., Marino, L., Ciardulli, M., Selleri, C., Forsyth, N., Giordano, E., Maffulli, N., Della Porta, G., Chondrogenic Commitment of human Bone Marrow Mesenchymal Stem Cells cultured under perfusion within a 3D collagen environment releasing hTGFβ1, submitted at Pharmaceutics, 2021.
- 2. Della Porta, G., Ciardulli, M.C., Maffulli, N., 2018. Microcapsule Technology for Controlled Growth Factor Release in Musculoskeletal Tissue Engineering. Sports Medicine and Arthroscopy Review 26.
- 3. Della Porta, G., Reverchon, E., Maffulli, N., 2017. Biomaterials and Supercritical Fluid Technologies: Which Perspectives to Fabricate Artificial Extracellular Matrix? Current Pharmaceutical Design 23, 3759-3771.
- 4. Ciardulli MC, Marino L, Lovecchio J, Giordano E, Forsyth NR, Selleri C, Maffulli N, Porta GD. 2020. Tendon and Cytokine Marker Expression by Human Bone Marrow Mesenchymal Stem Cells in a Hyaluronate/Poly-Lactic-Co-Glycolic Acid (PLGA)/Fibrin Three-Dimensional (3D) Scaffold. *Cells* **9**:1268.
- Palazzo I, Lamparelli EP, Ciardulli MC, Scala P, Maffulli N, Reverchon E, Santoro A, Della Porta G 2020. Supercritical emulsion extraction fabricated PLA/PLGA micro/nano carriers for growth factor delivery: Release profiles and cytotoxicity. International Journal of Pharmaceutics, 592, 120108
- Govoni, M., Lamparelli, E.P., Ciardulli, M.C., Santoro, A., Oliviero, A., Palazzo, I., Reverchon, E., Vivarelli, L., Maso, A., Storni, E., Donati, M.E., Ruspaggiari, G., Maffulli, N., Fini, M., Della Porta, G., Dallari, D., 2020. Demineralized bone matrix paste formulated with biomimetic PLGA microcarriers for the vancomycin hydrochloride controlled delivery: Release profile, citotoxicity and efficacy against S. aureus. International Journal of Pharmaceutics 582, 119322.